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Diagnosis, Management, and Pathogenetic Studies in Medullary 
Thyroid Carcinoma Syndrome 
Naguib A. Samaan,* Kuo-Pao Paul Yang,* Pamela Schultz,* and R.C. Hickey* 
A retrospective study of 224 patients with medullary thyroid carcinoma (MTC) diagnosed between 
1963 and 1988 was performed lo 1) establish the diagnosis of MTC in early childhood, 2) establish the 
role of prophylactic regional lymphadenectomy in patients wilh MTC, 3) sludy the effect of 
chemotherapy on MTC patients with metastatic disease, 4) sludy the effect of somatostatin analog 
201-995 (Sandoz Pharmaceuticals) on the frequency of diarrhea in MTC, and 5) locate the common 
region(s) of gene deletion on chromosome 1 and examine the loss of heterozygosity on chromosome 10 
in tumors. Our data indicated that a progressive rise of serum calcitonin in early childhood (raiher 
than the expected fall with age seen in normal subjects) is diagnostic of MTC. No differences in clinical 
course or prognosis were observed between patients wilh MTC localized lo the thyroid who had 
prophylactic neck node dissection and those who did not. Conventional chemotherapy had no 
significant benefit in the treatment of patients with metastatic disease. The somatostatin analog was 
found lo be an effeciive drug in the treatment of diarrhea associated with MTC. Allelic losses were 
frequently found in MTCs and pheochromocytomas, and the loss of DNA sequences in these tumors 
appeared to involve the distal third oflhe .short arm of chromosome 1, with a common breakpoint at 
lp32. (Henry Ford Hosp MedJ 1989:37:132-7) 
Over the last two decades much progress has been made in our understanding of the medullary thyroid carcinoma 
(MTC), both the hereditary and sporadic forms. However, many 
questions remain unanswered. This study addresses the fotlow-
ing five areas; 
1. We showed in 1973 (1,2) that seram calcitonin (CT) is ele-
vated at birth (Figs 1 and 2) and gradually decreases over time 
(3), and we proposed that high CT during intrauterine fetal life 
may be important for bone devetopment. These findings have 
been confirmed by others (4,5). The quesfion raised by these ob-
servations is how to establish the diagnosis of MTC at an early 
age when CT is physiologically elevated. 
2. Another important question is how much nodal dissection, 
if any, is needed when the disease is localized to the thyroid 
gland. 
3. Although we have shown that " ' I therapy for ablation ther-
apy of MTC is ineffective (6) and that radiotherapy post-
operatively is not beneficial (7), the role of various chemo-
therapeutic agents in advanced disease has not been thoroughly 
discussed because the number of patients reported in the liter-
ature is too smalt to reach a significant conclusion. 
4. A disabling dianhea can be the presenting manifestafion in 
30% of patients with MTC (8). However, various drugs have 
been used without success. We examined the possible benefits 
of the somatostatin (SMS) analog 201-995 (Sandoz Phar-
maceuficals) in MTC patients. 
5. We tested the hypothesis of suppressor gene inactivation in 
MTC and searched for the common region(s) of gene deletion on 
chromosome 1 and examined tumors also for toss of hetero-
zygosity for chromosome 10. 
Diagnosis of MTC at an Early Age 
An infant was bom with skeletal deformities in the form of 
clubbed feet and gastrointestinal signs of partial obstmction. A 
biopsy from the rectum showed neuromata similar to that seen in 
multiple endocrine neoplasia type 2B (MEN 2B), but the tips, 
tongue, and eyelids showed no neuromata. There was no family 
history of MTC or thyroid disease. Eye examination showed 
thickening of the comeat nerves. MTC was suspected, but the 
thyroid gland was clinically normal. Semm CT was measured 
basally and after pentagastrin .stimulation (Nichols Laboratory, 
San Juan Capistrano, CA). The basal CT level was 84 pg/mL 
with a peak of 200 pg/mL two minutes after intravenous admin-
istration of pentagastrin, which was considered to be within the 
normal range for infants of that age in that laboratory. Since we 
have observed previously in our laboratory that seram CT is high 
at birth and decreases with age in nonnal children, we elected to 
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Fig 1—Serum calcitonin levels in different age groups showing 
progressive decrease with age. (From Samaan NA, Anderson 
CD, Adam-Mayne ME. Immunoreactive calcitonin in the 
mother, neonate, child, and adult. Am J Obstet Gynecol 
1975:121:622-5. Reprinted with permission.) 
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Fig 2—Serum calcium (Ca), parathyroid hormone (PTH), and 
calcitonin (CT) in nonpregnant, maternal, and cord blood. 
Cord blood showed high serum calcium and CT and low PTH, 
whereas maternal blood showed subnormal calcium levels and 
high PTH and CT. (From Samaan NA, Wigoda C, Castillo SG. 
Human serum calcitonin and parathyroid hormone levels in the 
maternal, umbilical cord blood and postpartum. In: Endo-
crinology 1973. Proceedings of the Fourth International Sym-
posium. London: William Heinemann Medical Books, Ltd, 
1974:368. Reprinted with permission.) 
wait six months and repeat the pentagastrin stimulation test, par-
ficularly since the infant was marasmic due to difficulties in 
feeding. 
At the age of 14 months, seram CT was again measured dur-
ing pentagastrin stimulation in the same laboratory. The CT 
level showed an increase both at basal and after pentagastrin 
stimulation, which is contrary to what we observed in normal 
subjects with progress of age (3). The basal CT level was 107 pg/ 
mL with a peak of 312 at 2 minutes. Total thyroidectomy re-
vealed marked nodular C-cetl hyperplasia in the isthmus region. 
CT was again measured 16 months foltowing surgery and the 
basal levet was 14 pg/mL with no rise after stimulation with pen-
tagastrin. The patient is cunently in good heatth on thyroid 
replacement. 
MTC Localized to the Thyroid Gland: 
Indications for Nodal Dissection 
In the 224 patients diagnosed with MTC at The University of 
Texas M.D. Anderson Cancer Center from 1944 to 1988, the 
mean ± standard deviation of age at diagnosis was 43.0 ± 15.1 
years. The males comprise 46% of the population. Totat thy-
roidectomy had been performed in 75% of the patients. At the 
time of diagnosis the disease involved the thyroid gland and re-
gional lymph nodes in 36% and the thyroid gland alone in 35%. 
Extemal radiotherapy as an initial treatment had been performed 
in 28% and radioactive iodine has been given to 10% of the pa-
tients. MEN 2 had been identified in 24% of the patients. Local 
recunence in the neck had occurred in 30% and distant metasta-
ses have been documented in 37% of the patients. A total of 33% 
had died of MTC (Table I). To determine if prophylactic neck 
dissection was beneficial to the patients' outcome, those patients 
who presented with disease to the thyroid gland onty and who 
had neck dissection with negative lymph nodes (15 patients) 
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Table 1 
Population Characteristics of MTC Patients at The 
University of M.D. Anderson Cancer Center (1944-1988) 
and Localization of MTC at Presentation 
Population Characteristics Localization of MTC at Presentation 
Males: 103 (46%) Thyroid gland: 79 (35%) 
Mean Age (years) Thyroid gland and nodes: 81 (36%) 
± SD:45.5 ± 15.4 Thyroid gland, nodes, and soft 
tissue: 42 (22%) 
Females: 121 (54%) Thyroid gland, nodes. 
Mean Age (years) soft tissue, and 
± SD: 40.8 ± 14.6 distant metastasis: 18 (7%) 
Hereditary Cases: 24% 
were compared with those who had involvement of the thyroid 
gland onty and no neck dissection performed (43 patients). 
When these two groups of patients were analyzed according to 
age, sex, surgery, radiotherapy, radioactive iodine, MEN 2 syn-
drome, recurrence, and survival, no differences between the 
groups were found (Table 2), 
Radioactive Iodine, Radiotherapy, and 
Chemotherapy in the Treatment of MTC 
To determine the value of adjunct '-^'I therapy in MTC, two 
groups of patients with histologically proven MTC with lo-
calized disease to the thyroid gland only were studied. Group A 
consisted of 11 patients (six men and five women) treated by sur-
gery followed by an ablative dose of ' ^ ' I , and group B included 
46 patients (20 men and 26 women) treated by surgery atone. 
Patients in group A were followed for 1,5 to 14 years (median 
follow-up 53 months), and those in group B were followed for 
one to 27 years (median follow-up 75 months). We found no dif-
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Table 2 
Effect of Node Dissection of MTC Patients with LocaUzed 
Disease to the Thyroid (58 Patients) 
Node No node 
dissection dissection 
Number of patients 15 43 
Mean age (years) ± SD 37.5 ± 15.6 39.4 ± 14.5 
Males 4 (27%) 11 (26%) 
Females 11 (73%) 32 (74%) 
Total thyroidectomy 12 (80%) 35 (81%) 
< Total thyroidectomy 3 (20%) 8 (19%) 
X-ray treatment none none 
MEN 2 6 (40%) 15 (35%) 
Recurrence 6 (40%) 9 (21%)* 
Died 1 (7%) 6 (14%)* 
Mean follow-up (years) 11.9 ± 5.2 6.9 ± 5.1 
*P>0.1. 
ference in the two groups in the rate of recunence, metastasis, or 
survival (Fig 3). We atso saw no significant difference in the 
levet of CT between the two groups (6). 
We found that when patients who received radiotherapy were 
matched for age, extent of disease, and surgery with patients 
who had had no radiotherapy, the untreated group was found to 
live significantty longer (7) (P < 0.05) (Fig 4). 
Twenty-three patients with metastatic MTC were treated by 
various chemotherapeutic agents and 45 observations were re-
corded (some of the patients received more than one regimen) 
(Tabte 3). The drags used were adriamycin atone, adriamycin 
plus cisplarin, MeCCNU, and VP-t6, as well as other mis-
cellaneous drugs such as DTIC, vincristine, bleomycin, etc. 
The resutts were disappointing. None of the patients had com-
plete remission and few had partial or minor response. Com-
ptete remission was defined as disappearance of all evidence of 
tumor for at teast four weeks and the patient being free of atl 
symptoms of cancer. Partial response was defined as 50% or 
greater decrease in the products of the diameter of atl measured 
lesions for at least four weeks without increase in the size of any 
other lesions or appearance of new lesions. Minor response was 
defined as a decrease in a measurable lesion which is too small 
to qualify as a partial response, and failure indicated an increase 
in tumor size of at teast 25% or appearance of new lesions (Table 
3). 
Effect of SMS 201-995 on Diarrhea of MTC 
Two patients with severe dianhea were also studied. A 39-
year-old white mate who had MTC with lymph node and soft 
tissue involvement had surgery followed by radiotherapy to the 
neck. Over the last year he noticed severe diarrhea which in-
creased up to 35 stools per day. His CT was markedly elevated 
(> 500 ng/mL; normal; 0 to 1 ng/mL) and his carcinoembryonic 
antigen (CEA) was atso etevated (76 ng/mL; normal; 0 to 6 ng/ 
mL). He was given various drags for dianhea including lomotil, 
emodium, and paragoric with no significant beneficial effect. 
He was then given SMS 201-995, IOO |xg subcutaneously twice 
daily, and two drops of tincture of opium three fimes daily. His 
diarrhea decreased to 2 to 4 stools per day, and he gained 7.6 kg 
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Fig 3—Actuarial survival curves of patients with localized dis-
ease in both groups, showing no therapeutic effect of'-^'I in sur-
vival of patients with MTC. (From Saad MF, Guido JJ, Samaan 
NA. Radioactive iodine in the treatment of medullary carcinoma 
of the thyroid. J Clin Endocrinol Metab 1983 ;57;I24;8. Re-
printed with permission.) 
(17 lb) over a three-month period. The CT remained elevated (> 
500 ng/mL) as did the CEA (79 ng/mL). 
The second patient was a young, white female with MTC with 
metastases to the bone and skin. She had dianhea with 15 to 20 
stools per day and had tost a considerable amount of weight. She 
could not tolerate small amounts of food and felt nauseated and 
frequently vomited after meats. She was treated with SMS 
201-995, too |xg twice daily, and two drops of tincture of opium 
three times daily. She was no longer nauseated, had a good appe-
tite , and gained 8.tkg(t8tb)in three months. Her CT and CEA 
tevels were etevated at 190 ng/mL and 587 ng/mL, respectivety, 
before SMS 201-995 therapy and remained elevated at 220 ng/ 
mL and 603 ng/mL, respectivety, after three months of therapy. 
Both pafients atso showed nonnal 5-hydroxyindoteacetic acid 
(5HIAA) and seratonin before and after treatment with no 
change during therapy. The second patient took the tincture of 
opium less frequently and inegutarty without an increase in the 
frequency of dianhea. 
Molecular Analysis for Losses of DNA Sequences 
on Chromosomes 10 and lp 
Hsu et al (9) reported cytogenetic studies suggesting that 
MEN 2 patients exhibit some degree of chromosome instability. 
Hsu et at (10) atso showed that cultures of peripheral lympho-
cytes from patients with MEN 2 were more susceptible than nor-
mal individuats to mutagen-induced chromosomal breakage, 
with the frequent involvement of chromosomes I and 4. The 
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Table 3 
Effects of Chemotherapy in Medullary Thyroid Carcinoma 
in 23 Patients and 45 Observations 
Complete Partial Minimal 
Agents Number Response Response Response Failure 
Adriamycin 10 0 2 2 6 
Adriamycin -1- cisplatin 10 0 2 2 6 
Me CC Nu 3 0 0 0 3 
VP-16 2 0 0 1 I 
Miscellaneous 20 0 0 0 20 
higher frequency of spontaneous and induced chromosome ab-
errations in these patients woutd conceivably increase the proba-
bility of acquiring mutations at the target gene(s). However, in 
studies of 25 members of four MEN 2A families, Fenell et at 
(tt) failed to find evidence favoring linkage between the MEN 
2A mutation and genetic markers assigned to chromosomes 1 
and 4, 
Recent linkage studies (12,13) have assigned the predisposing 
gene for MEN 2A to chromosome 10, Since this predisposing 
mutation would most likely be expressed by toss of the homolo-
gous normal allele as suggested by Knudson in his two-hit 
model for carcinogenesis (14), we tested the hypothesis that the 
genetic etiology for MEN 2A is analogous to that for such child-
hood tumors as retinoblastoma and Wilms tumor. We examined 
the genotypes in constitutive and tumor cells from patients with 
MEN 2A at the interstitial retinol-binding protein (RBP3) locus 
which has been shown to link to MEN 2A (12,13,15), 
DNAs from eight patients with hereditary/sporadic MTC or 
pheochromocytoma were examined for the loss of hetero-
zygosity at the RBP3 locus by the Southern blot technique. 
However, none of the eight patients' genotypes were hetero-
zygous for the marker, and we were unable to assess whether or 
not one of the parental alleles of this chromosome 10 gene is lost 
in their tumors, Flejter et at (16) recentty reviewed high-resolu-
fion chromosome preparations from 23 MEN 2 families and 
found no apparent abnormalities invotving chromosome 10, 
Landsvater et at (17) and Nelkin et at (18) reported that the inci-
dence of reduction to homozygosity for chromosome 10 DNA 
markers in tumor DNA from MEN 2 patients was uncommon. 
Nevertheless, the possibility remains that submicroscopic dele-
tion or point mutation may exist in the chromosome 10 loci in 
these tumor DNAs and may have escaped detection by these 
studies. Therefore, the nature of mechanisms invotving chro-
mosomes to in MEN 2 which resutt in the second mutational 
event remains unclear, 
Mathew et al (19) reported that toss of heterozygosity on chro-
mosome tp was detectable in seven of 14 informative patients 
with MTC or pheochromocytoma from both hereditary and spo-
radic cases. Simitar mutations at chromosome tp were atso 
frequently detectable in neuroblastomas (20), a tumor which is 
derived from the same embryonic origin as MEN 2. In other 
types of tumors such as colorectal tumors and small cett car-
cinomas of the lung, multiple mutations invotving different 
chromosomes have been implicated as the genetic mechanisms 
for tumor initiation and progression (21-23). In tight of these 
findings, we performed molecular anatysis aimed at determin-
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Fig 4—Comparison of survival in MTC patients matched for 
age, extent of disease, and surgery. External radiation showed 
no benefit, and those who received radiotherapy had shorter 
survival than those who did not. (From Samaan NA, Schultz PN, 
Hickey RC. Medullary thyroid carcinoma; Prognosis of familial 
versus sporadic disease and the role of radiotherapy. J Clin En-
docrinol Metab 1988;67;801-5. Reprinted with permission.) 
ing the region on chromosome tp that may represent a common 
deletion in MEN 2A in order to locate the potential tumor sup-
pressor gene whose mutation is invotved in the processes of 
tumorigenesis. 
Five polymorphic DNA probes (PND,FUCAt, D1S57, L-
myc, and NGFB) that detect various chromosome tp loci plus a 
tq marker (AT3) were used to examine allelic deletions for chro-
mosome 1. Among the eight patients, allelic deletion at the L-
myc locus was clearly demonstrated by the loss of hetero-
zygosity in two patients (Fig 5, cases 3 and 5) and by the reduc-
tion of about 50% of the gene copies in another two patients (Fig 
5, cases 2 and 4) whose constitutional alleles were homozygous 
at this locus. In the remaining four patients, whose constitu-
tional DNAs were homozygous to this marker, the status of gene 
deletion/inactivation at this locus could not be assessed. Patient 
2's tumor DNA atso had multiple deletions at four loci between 
tp32 and lp36, suggesting deletion of the distal third of tp. Tu-
mor DNAs from four patients (cases 3,4,5, and 6) tost hetero-
zygosity at one or two loci within the distal third of tp, suggest-
ing interstitial deletions. Tumor DNA from patient 1 showed 
abnormal band pattems in regions of DtS57 and FUCAl loci, 
suggesting gene reanangement in the distal third of lp of this 
tumor. The common region of gene deletion on chromosome tp 
in these eight MEN 2A-associated tumors was determined to be 
lp32 (Fig 6), 
Discussion 
We have previousty shown that CT is etevated in infants at 
birth as wett as in the pregnant mother. We suggested that the 
high CT in the presence of high serum calcium during intra-
uterine fetal life may play a rote in the bone formation of the 
fetus. We atso suggested that the high CT in the mother may play 
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Fig 5—Allelic deletion (patients 2, 3,4, and 5) at locus Ip32 in 
eight cases of MTC and pheochromocytoma. DNAs were di-
gested with EoRI. Upper panel: Southern hybridization patterns 
ofthe 32p-labeled L-myc probe to DNAs from peripheral blood 
leukocytes (L) and tumor cells (T)from each patient. Patient 
numbers are indicated below the blots. Numbers to the right of 
autoradiographs indicate the molecular size ofthe two poly-
morphic alleles in kilobases. Lower panel; Densitometric scans 
of Southern hybridizations with 32P-labeled L-myc probe in 
cells from patients 2 and 4. Solid lines represent the readings for 
leukocyte DNA, and dotted lines represent those for tumor DNA. 
A ^-globin gene probe serves as a control for normalization of 
the hybridization intensity. 
Fig 6—A summary ofthe allelic deletion on chromosome Ip in 
the eight cases of MTC and pheochromocytomas studied. Open 
boxes represent regions where patients' leukocyte DNA was het-
erozygous and tumor DNA showed loss of an allele; boxes with 
vertical lines represent areas where patients' leukocyte DNA 
was homozygous and tumor DNA showed an approximately 
50% reduction in band intensity; solid boxes represent areas 
where constitutional heterozygosity was retained in the tumors; 
boxes with unidirectional diagonal lines represent regions 
where patients' leukocyte DNA was homozygous and therefore 
allelic deletion could not be assessed; boxes with crossed diago-
nal lines represent regions where patients' tumor DNA revealed 
abnormal or new restriction fragments. The solid lines repre-
sent areas that we have not yet examined. 
a rote in inhibiting the bone resorption in the presence of high 
matemal parathyroid hormone which increases the absorption of 
seram calcium from the gastrointestinal tract and reabsorption 
ofthe calcium from the renal tubules, and thus calcium will be 
available to the fetus (1,2). We have also shown that CT levels 
decrease with age (3). These observations were confirmed by 
others (4,5). However, the presence of elevated CT levels in 
childhood presents major problems for diagnosis of MTC early 
in life. We propose that if MTC or C-cell hyperplasia is sus-
pected in early life, such as in our described patient, or in other 
MEN 2 family members, the measurement of CT at various in-
tervals in early life and the finding of the progressive rise in CT 
rather than the expected fall may provide a diagnosis. This prop-
osifion is confirmed in the patient described. 
The extent of surgery which is indicated in the treatment of 
MTC localized to the thyroid gland has been controversial 
(24-26). Our data suggest that ifthe lymph node sampling shows 
the middle compartment of the neck to be free of disease, no 
lymph node dissection is necessary. We suggest that other cen-
ters should examine their findings in this regard. 
We previously reported that radioactive ablation for patients 
with MTC failed to affect the remission or survival rate (6). We 
also reported that when patients who received radiotherapy after 
surgery for MTC were matched for age, extent of disease, and 
surgery with patients who had no radiotherapy, the untreated 
group was found to live significantly longer (7). We also showed 
that adriamycin, cisplatin, and bleomycin had little tumoricidal 
effects when administered as a single agent to cultured human 
MTC cells (27,28). Our present findings also indicate that the 
chemotherapy (such as adriamycin alone or in combination with 
cisplatin or other drags such as bleomycin, vincristine, 5-fluo-
rouracil, and methotrexate) has no measurable beneficial effect. 
Diarrhea in MTC may be the presenting symptom in 30% of 
patients (8) andean be disabling. Our results in two patients sug-
gest that SMS 201-995 either alone or with tincture of opium is 
effective in the treatment of diarrhea of MTC. The mechanism of 
action is unclear since there was no significant change in the CT 
level before and after treatment as well as no change in CEA, 
serofinin, or the 24-hour urinary 5HIAA. The somatostatin ana-
log may act on the peripheral tissue or through an inhibition of a 
hormone, the nature of which is unknown. 
The present study on pathogenetic mechanisms in MEN 2A 
suggests that a tumor suppressor gene for MTC and pheo-
chromocytoma might be located at the distal third of lp (most 
likely at lp32) where mutant alleles seem to be involved in the 
initiation and/or progression of these tumors. However, in view 
ofthe evidence reported by others (21-23) suggesting that sev-
eral tumor suppressor genes on different chromosomes may be 
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invotved in suppressing the malignant phenotype in simitar but 
distinct tumor types, it is possible that heterozygosity might be 
tost frequently at other chromosomal loci atso. 
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